Status:
COMPLETED
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Conditions:
Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will determine the overall response rate and toxicity of rituximab and Velcade in combination in patients with relapsed or refractory mantle cell non-Hodgkin's lymphoma.
Detailed Description
Rationale: Previous studies testing bortezomib and rituximab separately indicate these agents have some efficacy against mantle cell lymphoma (MCL). Bortezomib is a targeted cancer drug that blocks pr...
Eligibility Criteria
Inclusion
- Histologically confirmed mantle cell or follicular lymphoma
- Relapsed or refractory disease
- ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, 2 or 3
Exclusion
- Pre-existing sensory or motor peripheral neuropathy
- No active or untreated CNS (Central Nervous System) lymphoma
- History of severe, life-threatening hypersensitivity or infusion reactions prior rituximab treatment.
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00201877
Start Date
December 1 2004
End Date
March 1 2012
Last Update
March 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University Medical Center
Columbus, Ohio, United States, 43210